Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Article

Activation of Insulin-Reactive CD8 T-Cells for Development of Autoimmune Diabetes

  1. F. Susan Wong1,
  2. Lai Khai Siew1,
  3. Gwen Scott1,
  4. Ian J. Thomas1,
  5. Stephen Chapman1,
  6. Christophe Viret2 and
  7. Li Wen3
  1. 1Department of Cellular and Molecular Medicine, University of Bristol, Bristol, U.K.; the
  2. 2Centre de Physiopathologie de Toulouse Purpan, INSERM, U563-BAT A CHU Purpan, Toulouse, France; and the
  3. 3Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut.
  1. Corresponding author: Susan Wong, susan.wong{at}bristol.ac.uk.
Diabetes 2009 May; 58(5): 1156-1164. https://doi.org/10.2337/db08-0800
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Comparison of thymocytes and splenocytes from G9NOD transgenic mice and nontransgenic NOD mice. A–C: Cells from G9NOD transgenic mice. D–F: Cells from nontransgenic NOD mice. A and D: Thymocytes single-positive CD4 and anti-CD8. B and E: Splenocytes stained with anti-CD4 and anti-CD8. C and F: Splenocytes stained with anti-CD8 and a pool of anti-Vα2, -3, -8, and -11. The results are representative of 15 transgenic mice in more than five independent experiments. The mean (SD) values for the cell populations are as follows: A: CD4 3.46 (1.71); CD8 5.89 (2.28). B: CD4 17.38 (4.91); CD8 20.35 (3.77). C: CD8Vα2, -3, -8, -11 negative 20.0 (4.1); CD8Vα2, -3, -8, -11 positive 3.8 (1.9). D: CD4 10.2 (1.9); CD8 4.7 (0.7). E: CD4 40.63 (5.6); CD8 17.07(1.9). F: CD8Vα2, -3, -8, -11 negative 15.36 (1.03); CD8Vα2, -3, -8, -11 positive 1.85 (0.08).

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Phenotype of G9Cα−/−.NOD mice and G9RAG−/−.NOD mice. G9Cα−/−.NOD thymocytes (A), splenocytes (B), and PLN cells (C) were stained with anti-CD4 and -CD8. D: PLN cells were stained with anti-Vβ6 and CD8. E: Gated CD8 T-cells were stained with Kd-B15-23 (bold line) and control Kd-LLO 91–99 (dotted line) tetramer, respectively. G9RAG−/−.NOD thymocytes (F), splenocytes (G), and PLN cells (H) were stained with anti-CD4 and -CD8. I: PLN cells were stained with anti-Vβ6 and CD8. The results represent three independent experiments. The mean (SD) values for the distribution of cell populations are as follows: A: CD4 1.43 (0.42); CD8 5.1 (1.6). B: CD4 8.28 (1.35); CD8 21.14 (4.62). C: CD4 6.28 (0.57); CD8 52.18 (9.26). F: CD4 0.85 (0.44); CD8 2.93 (1.22). G: CD4 2.21 (2.16); CD8 33.42 (6.94). H: CD4 1.18 (0.66); CD8 68.7 (13.32).

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Functional responses of purified CD8 T-cells from G9Cα−/−.NOD mice. A: Cytotoxic assay of insulin-reactive CD8 T-cells directly ex vivo (○) from G9Cα−/−.NOD mice compared with precultured cells (●) in response to increasing B15-23 peptide concentrations at an E:T ratio of 10:1. B: Intracellular IFN-γ and TNF-α production in response to increasing concentrations of insulin B15-23 peptide after a 40-h culture. C: 3H-Thymidine incorporation proliferation assay of splenocytes from G9Cα−/−.NOD mice in response to B15-23 peptide and to influenza hemagglutinin (flu HA) control peptide. ●, Ins B15-23; ○, flu HA. D: 3H-Thymidine incorporation proliferation assay of splenocytes from G9Cα−/−.NOD mice in response to cross-presented insulin protein or control KLH. The results were from one of four independent experiments.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    The role of CD4 T-cells. A: 3H-Thymidine incorporation proliferation assay of CD8, CD4, and mixed CD8 and CD4 splenocytes from G9Cα−/−.NOD mice in response to B15-23 peptide G9Cα−/−. B: Adoptive transfer of purified CD4 T-cells of splenocytes from diabetic NOD intravenously into 4-week-old G9Cα−/−.NOD mice (n = 16). No diabetes occurred in mice adoptively transferred with CD4 T-cells purified from young NOD mice (n = 5). P < 0.018 when both groups were compared. The mice were tested weekly for glycosuria and diabetes confirmed by blood glucose of >13.9mmol/l.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Activated CD8 T-cells from G9Cα−/−.NOD mice cause diabetes. A: G9Cα−/−.NOD mice were immunized with B15-23 peptide (50 μg) together with CpG oligonucleotides at different doses (two injections, 9–21 days apart). Diabetes was seen after the second injection in the majority of mice and the graph illustrates the mice, following the second injection, immunized with peptide plus 65 μg CpG (●), peptide plus 100 μg CpG (○), and peptide plus 195 μg CpG (▵). Two of four mice immunized with peptide, and high-dose CpG (195 μg) actually developed diabetes before the second injection and the remaining two mice are shown in the graph. None of the control mice injected with peptide alone (n = 11) or the various doses of CpG alone (n = 13) developed diabetes (data not shown). P < 0.0001 when all groups were compared. B: Flow cytometry of spleen cells from a nonimmunized G9Cα−/−.NOD mouse, gated on CD8 T-cells, shown in the thin line, compared with cells from a diabetic mouse after CpG and peptide immunization, shown in the thick line. The upper panel shows upregulation of CD44 and the lower panel illustrates downregulation of CD62L. C: Histology showing sections from diabetic G9Cα−/−.NOD mouse immunized with CpG and peptide (top row), CpG alone (middle row), and peptide alone (bottom row), stained with anti-CD8, anti-CD4, and anti-B220 (B-cells). (A high-quality representation of this figure is available in the online issue.)

  • FIG. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Adoptive transfer of purified activated G9Cα−/−.NOD CD8 T-cells into NOD.scid mice. G9Cα−/−.NOD CD8 T-cells were purified and cultured with matured bone marrow–derived dendritic cells together with 0.5 μg/ml insulin B15-23 peptide for 3 days. After washing, the cells were intravenously injected into 6-week-old NOD.scid mice (n = 8). Mice were tested daily for glycosuria and diabetes confirmed by blood glucose >13.9mmol/l.

  • FIG. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Diabetes incidence in G9Cα−/−.RIP-B7.1 NOD mice. G9Cα−/−.NOD mice that also expressed RIP-B7.1 transgene (●, n = 18) were compared with nontransgenic G9Cα−/−.NOD mice (○, n = 20) and observed for diabetes. Mice were tested weekly for glycosuria and diabetes confirmed by blood glucose >13.9 mmol/l (P < 0.0001).

  • FIG. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    Insulin-reactive CD8 T-cells proliferate only in PLNs but not in the spleen, MLN, or ALN when adoptively transferred into NOD mice. CFSE-labeled purified G9Cα−/−.NOD CD8 T-cells were injected iv into 4-week-old NOD mice and the lymphoid tissue extracted and cells analyzed in PLNs (A) and spleen (B). The cells were gated on CD8 T-cells, and CFSE-labeled cells, costained with anti-CD69, are shown from PLNs (A) and spleen (B). Percentage proliferation of divided cells is shown after gating on CD8 T-cells from PLNs (C) and spleen (D). Proliferation in MLN and ALN was similar to spleen (data not shown). All groups were compared by ANOVA P = 0.014.

PreviousNext
Back to top

In this Issue

May 2009, 58(5)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Activation of Insulin-Reactive CD8 T-Cells for Development of Autoimmune Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Activation of Insulin-Reactive CD8 T-Cells for Development of Autoimmune Diabetes
F. Susan Wong, Lai Khai Siew, Gwen Scott, Ian J. Thomas, Stephen Chapman, Christophe Viret, Li Wen
Diabetes May 2009, 58 (5) 1156-1164; DOI: 10.2337/db08-0800

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Activation of Insulin-Reactive CD8 T-Cells for Development of Autoimmune Diabetes
F. Susan Wong, Lai Khai Siew, Gwen Scott, Ian J. Thomas, Stephen Chapman, Christophe Viret, Li Wen
Diabetes May 2009, 58 (5) 1156-1164; DOI: 10.2337/db08-0800
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Article

  • An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
  • Loss of Prohibitin Induces Mitochondrial Damages Altering β-Cell Function and Survival and Is Responsible for Gradual Diabetes Development
  • Cbl-b Is a Critical Regulator of Macrophage Activation Associated With Obesity-Induced Insulin Resistance in Mice
Show more Original Article

Immunology and Transplantation

  • One in Ten CD8+ Cells in the Pancreas of Living Individuals With Recent-Onset Type 1 Diabetes Recognizes the Preproinsulin Epitope PPI15-24
  • Peptidylarginine Deiminase Inhibition Prevents Diabetes Development in NOD Mice
  • Differentiating MHC-Dependent and -Independent Mechanisms of Lymph Node Stromal Cell Regulation of Proinsulin-Specific CD8+ T Cells in Type 1 Diabetes
Show more Immunology and Transplantation

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.